Navigation Links
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™(*)) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity
Date:10/5/2011

PARIS, Oct. 5, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The New England Journal of Medicine (NEJM).  Results showed that teriflunomide at the 14mg dosage significantly reduced the annual relapse rate, reduced disability progressions and improved several magnetic resonance imaging (MRI) measures of disease activity, including new or worsening brain lesions.  Teriflunomide has a well-characterized safety profile, with a similar proportion of trial participants reporting adverse events compared to placebo.

"The TEMSO data demonstrate the effect of teriflunomide in terms of reducing relapse rates, disability progression and Magnetic Resonance Imaging (MRI) lesions," said Dr. Paul O'Connor, Director of the MS Clinic at St Michael's Hospital, Toronto, Canada and principal investigator in the TEMSO study.  "These results, sustained over two years, provide clinically meaningful data for teriflunomide."

The two-year TEMSO (TEriflunomide Multiple Sclerosis Oral) trial involved 1,088 people with relapsing forms of MS from 126 centers across 21 countries. TEMSO is the first study from a broad clinical development program that includes more than 4,000 trial participants in 36 countries and is one of the largest and broadest clinical programs of any oral MS agent under development, with five Phase III clinical trials either completed or underway.

"The publication of the teriflunomide results in the New England Journal of Medicine is an exciting milestone as we continue the development of our product," said Dr. Elias Zerhouni, President, Global Research & Development, Sanofi. "As we continue our commitment t
'/>"/>

SOURCE Sanofi; Genzyme
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
2. Positive Phase III Data on Bayers Investigational Drug Radium-223 Chloride Show Significant Increase in Overall Survival
3. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
4. Bayer to Present New Data Evaluating Investigational Oncology Compounds at 2011 ECCO-ESMO Congress
5. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
6. FDA Grants Fast Track Designation to Bayers Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
7. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
8. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
9. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
10. Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Associations 71st Annual Scientific Sessions
11. Morphotek, Inc. Announces That Two Investigational Drugs Have Received Orphan Drug Designations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... -- Actavis plc (NYSE: ACT ) announced today ... and Drug Administration (FDA) as a twice-daily, oral ... with diarrhea (IBS-D). VIBERZI (eluxadoline) has mixed opioid ... a delta receptor antagonist, and a kappa receptor ... "The FDA,s approval of VIBERZI is ...
(Date:5/27/2015)... Madison Laser Tattoo Removal is the first laser tattoo ... the surrounding area to offer treatments with the Astanza Duality. ... dedicated to bringing a solution to those living with tattoo ... "I founded Madison Laser Tattoo Removal to give patients a ... its natural look," said Emily Livesey, RN and ...
(Date:5/27/2015)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life sciences ... of innovative products and services, today announced that its ... operations in Grand Rapids, Michigan ... , North Carolina.  Sequenom Laboratories, cystic fibrosis carrier screen ... North Carolina laboratory location.  "The ...
Breaking Medicine Technology:Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 2Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 3Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 4Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults 5Madison Laser Tattoo Removal Brings Superior Laser Tattoo Removal Services To Madison, WI With Astanza Duality 2Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 2Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 3
... , , SAN FRANCISCO , Feb. ... Board: MZEI) announced today that every full scale test ... has resulted in the total elimination of all bacteria present ... Medizone,s scientific team will attempt to confirm, in a more ...
... NEW YORK , Feb. 4 Delcath Systems, Inc. ... treatment system for metastatic cancers to the liver, announced today that ... on its Phase III trial.  The trial uses the drug melphalan ... "We remain very optimistic that the Phase III trial will achieve ...
Cached Medicine Technology:AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs 2AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs 3Delcath Systems Begins Data Analysis of Phase III Trial 2Delcath Systems Begins Data Analysis of Phase III Trial 3
(Date:5/27/2015)... 27, 2015 In today's healthcare landscape, ... it can be challenging for doctors and hospitals to ... treatments. , Austin-based HealthTronics, Inc. is ... mobile medical therapies for clinically sophisticated applications. The company ... acquisition of Laser Ventures, Inc ., a mobile ...
(Date:5/27/2015)... 2015 Dr. Omar Ibrahimi, Dermatologist and ... CT has been selected as part of a controlled ... (and the only physician in Connecticut) to offer the ... the removal of submental fat (double chin). The procedure ... no surgery and minimal risks. Dr. Ibrahimi is an ...
(Date:5/27/2015)... NOVAtime Technology, Inc. ( http://www.novatime.com ), a leading ... announced today that SanMar Corporation successfully implemented the ... and point tracking processes for over 3,000 employees ... , Family-owned since 1971, Seattle-based SanMar Corporation is ... and mill brands. SanMar supplies apparel and accessories ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 In support ... April 2015 issue of the Journal of American Geriatrics ... and abdominal obesity, Bedford Commons OB-GYN P.A . ... of non-nutritive sweetener-flavored beverages. , To examine the ... a comprehensive San Antonio Longitudinal Study of Aging (SALSA) ...
(Date:5/27/2015)... AR (PRWEB) May 27, 2015 ... today announce a partnership to provide CMSA's Career ... community. This collaboration seeks to strengthen the case/care ... through CMSA’s CKP program. The mutually beneficial agreement ... identifying individual skills of talent in the healthcare, ...
Breaking Medicine News(10 mins):Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3
... tea extract has recently achieved GRAS (Generally Recognized As ... US a strong signal of the ingredient’s suitability in ... being used in a number of supplement products in ... Vitamin Shoppe and Healthy Origins, American food companies say ...
... that postmenopausal women would have lesser chance of losing their ... Their research was published in the latest issue of Journal ... had found that in an average of 11 years, at ... says that alveolar bone loss is one of the most ...
... South Wales may be one of the first scientists to ... there is no single test that could exactly identify the ... the latest issue of the journal Psychiatry Research said that ... cost effective as their tool can safely distinguish between the ...
... to be in slumber for the past 11 months, baffling doctors ... Arup Manna of Panskura in East Midnapore district was an active ... suddenly started falling asleep., ,The meritorious boy, who used to ... for feeding and answering nature's call., ,The boy's mother says ...
... of morbidity and mortality in India. An attempt to formulate// ... many young lives, is worth the expense., , India ... a new vaccine for a deadly form of diarrhoea that ... been accelerated after phase I clinical trials showed up to ...
... soy Z-Trim fat replacer at a recent show //in New ... a variety of products without altering the food's original taste. ... soy Z-Trim fat replacer at a recent show in New ... 55 symposia and 14,000 attendees. , ,According to the ...
Cached Medicine News:Health News:Yet Another Use For Green Tea Extract 2Health News:New Insight In Periodontal Disease In Postmenopausal Women 2Health News:Schizophrenia Gets A New Diagnostic Tool 2Health News:New Oat And Soy-Based Fat Replacer Launched 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: